Rezultati - Xiaomin Wan
- Showing 1 - 4 results of 4
-
1
First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis... od Xiaomin Wan, Xia Luo, Chongqing Tan, Xiaohui Zeng, Yucong Zhang, Liubao Peng
Izdano 2019Artigo -
2
-
3
-
4
Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Can... od Chongqing, Tan, Sini, Li, Xiaohui, Zeng, Liubao, Peng, Ye, Peng, Shuxia, Qin, Liting, Wang, Meiyu, Wu, Xiaomin, Wan
Izdano 2021Text
Iskalna orodja:
Sorodne teme
Cancer
Immunotherapy
Internal medicine
Lung cancer
Medicine
Oncology
Alternative oxidase
Arabidopsis
Arabidopsis thaliana
Atezolizumab
Bevacizumab
Biochemistry
Biology
Carboplatin
Cell biology
Cellular respiration
Chemotherapy
Cisplatin
Cost effectiveness
Cytosol
Docetaxel
Enzyme
Gene
Intensive care medicine
Mitochondrion
Mutant
Nivolumab
Organelle
Paclitaxel
Pembrolizumab